111 related articles for article (PubMed ID: 1675413)
1. The role of lipophilicity in the inhibition of polymorphic cytochrome P450IID6 oxidation by beta-blocking agents in vitro.
Ferrari S; Leemann T; Dayer P
Life Sci; 1991; 48(23):2259-65. PubMed ID: 1675413
[TBL] [Abstract][Full Text] [Related]
2. High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.
Kronbach T; Mathys D; Gut J; Catin T; Meyer UA
Anal Biochem; 1987 Apr; 162(1):24-32. PubMed ID: 3605590
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes.
Le Guellec C; Lacarelle B; Catalin J; Durand A
Cancer Chemother Pharmacol; 1993; 32(6):491-5. PubMed ID: 8258200
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450IID subfamily in non-human primates. Catalytical and immunological characterization.
Jacqz-Aigrain E; Gueguen M; Zanger UM; Robieux I; Alvarez F
Biochem Pharmacol; 1991 Jun; 41(11):1657-63. PubMed ID: 2043154
[TBL] [Abstract][Full Text] [Related]
5. The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6.
Madeira M; Levine M; Chang TK; Mirfazaelian A; Bellward GD
Drug Metab Dispos; 2004 Apr; 32(4):460-7. PubMed ID: 16680870
[TBL] [Abstract][Full Text] [Related]
6. Primary and secondary oxidative metabolism of dextromethorphan. In vitro studies with female Sprague-Dawley and Dark Agouti rat liver microsomes.
Kerry NL; Somogyi AA; Mikus G; Bochner F
Biochem Pharmacol; 1993 Feb; 45(4):833-9. PubMed ID: 8452558
[TBL] [Abstract][Full Text] [Related]
7. Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver.
Broly F; Libersa C; Lhermitte M; Bechtel P; Dupuis B
Br J Clin Pharmacol; 1989 Jul; 28(1):29-36. PubMed ID: 2775613
[TBL] [Abstract][Full Text] [Related]
8. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.
Brosen K
Clin Pharmacokinet; 1990 Mar; 18(3):220-39. PubMed ID: 2182263
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation.
Schmider J; Greenblatt DJ; von Moltke LL; Harmatz JS; Shader RI
Br J Clin Pharmacol; 1996 Apr; 41(4):339-43. PubMed ID: 8730981
[TBL] [Abstract][Full Text] [Related]
10. Demethylation of radiolabelled dextromethorphan in rat microsomes and intact hepatocytes.
Di Marco A; Yao D; Laufer R
Eur J Biochem; 2003 Sep; 270(18):3768-77. PubMed ID: 12950260
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of major drug metabolizing cytochrome P450 isozymes in human liver microsomes by carbon monoxide.
Leemann T; Bonnabry P; Dayer P
Life Sci; 1994; 54(14):951-6. PubMed ID: 8139385
[TBL] [Abstract][Full Text] [Related]
12. The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes.
Kerry NL; Somogyi AA; Bochner F; Mikus G
Br J Clin Pharmacol; 1994 Sep; 38(3):243-8. PubMed ID: 7826826
[TBL] [Abstract][Full Text] [Related]
13. Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6.
Kronbach T
Methods Enzymol; 1991; 206():509-17. PubMed ID: 1686064
[No Abstract] [Full Text] [Related]
14. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).
Tyndale RF; Kalow W; Inaba T
Br J Clin Pharmacol; 1991 Jun; 31(6):655-60. PubMed ID: 1867960
[TBL] [Abstract][Full Text] [Related]
15. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities?
Yu A; Haining RL
Drug Metab Dispos; 2001 Nov; 29(11):1514-20. PubMed ID: 11602530
[TBL] [Abstract][Full Text] [Related]
16. UPLC-MS/MS analysis of dextromethorphan-O-demethylation kinetics in rat brain microsomes.
DuBois BN; Mehvar R
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Oct; 1096():66-72. PubMed ID: 30149296
[TBL] [Abstract][Full Text] [Related]
17. Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo.
Haefeli WE; Bargetzi MJ; Follath F; Meyer UA
J Cardiovasc Pharmacol; 1990 May; 15(5):776-9. PubMed ID: 1692938
[TBL] [Abstract][Full Text] [Related]
18. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes.
Zhang WV; D'Esposito F; Edwards RJ; Ramzan I; Murray M
Drug Metab Dispos; 2008 Dec; 36(12):2547-55. PubMed ID: 18809730
[TBL] [Abstract][Full Text] [Related]
19. Dextromethorphan O-demethylation polymorphism in Jordanians.
Irshaid YM; al-Hadidi HF; Rawashdeh NM
Eur J Clin Pharmacol; 1993; 45(3):271-3. PubMed ID: 8276053
[TBL] [Abstract][Full Text] [Related]
20. Interaction of a series of beta-adrenergic blocking drugs with rat hepatic microsomal monooxygenase.
Facino RM; Lanzani R
Pharmacol Res Commun; 1979 May; 11(5):433-45. PubMed ID: 39298
[No Abstract] [Full Text] [Related]
[Next] [New Search]
